Grifols (NASDAQ:GRFS) Rating Lowered to “Buy” at Wall Street Zen

Grifols (NASDAQ:GRFS) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

A number of other brokerages have also recently issued reports on GRFS. JPMorgan Chase & Co. lowered their price objective on Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a research note on Monday, December 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Grifols in a research note on Thursday, January 22nd. Finally, Zacks Research upgraded Grifols from a “strong sell” rating to a “hold” rating in a research report on Friday, February 6th. Four equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

Grifols Stock Up 1.6%

Shares of NASDAQ GRFS opened at $9.10 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.48 and a quick ratio of 0.93. The stock has a fifty day simple moving average of $9.22 and a two-hundred day simple moving average of $9.36. Grifols has a 1-year low of $6.19 and a 1-year high of $11.14.

Institutional Trading of Grifols

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Allworth Financial LP raised its position in Grifols by 15.7% during the fourth quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 1,096 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Grifols by 2.4% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 47,192 shares of the biotechnology company’s stock valued at $427,000 after buying an additional 1,114 shares during the period. Cerity Partners LLC lifted its position in Grifols by 6.3% in the fourth quarter. Cerity Partners LLC now owns 19,121 shares of the biotechnology company’s stock worth $179,000 after buying an additional 1,131 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Grifols by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 1,212 shares during the last quarter. Finally, Versant Capital Management Inc raised its stake in shares of Grifols by 39.5% in the third quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 1,584 shares during the period.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.